Latigo Biotherapeutics

Mar 17, 2025

Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics

Nov 19, 2024

Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair

Oct 16, 2024

Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain

Sep 09, 2024

Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors

Feb 14, 2024

Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines